Mirum Pharmaceuticals, Inc.
MIRM
$44.02
-$0.37-0.83%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 51.22% | 46.18% | 39.21% | 38.08% | -22.74% |
| Total Depreciation and Amortization | 60.82% | 118.21% | 238.88% | 274.62% | 244.83% |
| Total Amortization of Deferred Charges | 9.73% | 48.70% | 128.97% | 431.27% | -- |
| Total Other Non-Cash Items | -44.42% | -52.76% | -39.29% | -41.26% | 174.96% |
| Change in Net Operating Assets | -241.99% | 229.03% | 191.81% | 159.49% | 174.38% |
| Cash from Operations | 81.47% | 114.55% | 98.62% | 75.70% | 62.76% |
| Capital Expenditure | -1,160.49% | -811.01% | -177.21% | -114.05% | 74.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -233.85% | -184.35% | -168.16% | -274.63% | 5,462.55% |
| Cash from Investing | 20.85% | 15.93% | -18.26% | -1,138.65% | -7,419.78% |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -89.25% | -92.21% | -93.64% | 102.68% | 90.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 99.86% | 99.86% | -2,413.35% |
| Cash from Financing | -92.96% | -94.74% | -95.77% | 1.86% | 212.42% |
| Foreign Exchange rate Adjustments | -70.67% | -875.19% | 221.79% | -254.35% | -202.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -159.05% | -140.04% | -147.62% | -144.90% | 4,775.25% |